Shares of Ecovyst jumped 11.1% to $12.71 in after-hours trading after the specialty chemicals maker beat Wall Street estimates on both profit and revenue, then raised its full-year guidance. The question for shareholders now is whether the numbers justify the enthusiasm — or whether acquisition-fueled growth is masking thinner profits underneath.
A Clean Beat on Top and Bottom Lines, But Margins Tell a Different Story
Ecovyst reported adjusted earnings of $0.21 per share on revenue of $250 million, topping forecasts of $0.19 and $237.5 million, respectively.
Sales climbed 42% year over year while diluted EPS from continuing operations rose to $0.10 from $0.04. Yet the raw growth rate flatters the picture. Adjusted EBITDA (a measure of operating profit before certain accounting items) increased 27% to $53.1 million, but its margin fell to 21.2% from 23.8% because sulfur cost pass-throughs pushed revenue up faster than actual profit. Revenue is growing nearly twice as fast as earnings — a gap investors should watch.
The $190 Million Calabrian Deal Closed Just in Time to Pad the Outlook
Ecovyst completed its acquisition of the Calabrian sulfur dioxide and derivatives business from INEOS Enterprises on June 30, 2026 — the quarter's final day, meaning Calabrian is expected to contribute just $10–$12 million of adjusted EBITDA in the second half of 2026.
Ecovyst financed the deal partly with a $100 million incremental term loan , adding leverage at a time when investors may already be focused on balance-sheet leverage and the effect of higher sulfur prices on working capital.
Full-Year Guidance Now Points to a Billion-Dollar Revenue Company
Ecovyst raised 2026 sales guidance to $1.02–$1.06 billion and adjusted EBITDA guidance to $195–$207 million , with adjusted diluted EPS projected at $0.58–$0.72 and free cash flow of $45–$55 million. At the midpoint, that implies the stock trades at roughly 10× EBITDA — not expensive for a company growing this fast, but not cheap for one whose virgin sulfuric acid sales are expected to be lower than 2025 due to fewer spot sales opportunities.
Diversification Sounds Good, But Integration Risks Are Real
The deal diversifies Ecovyst into sulfur dioxide derivatives serving mining, water treatment, food processing, and pharmaceuticals. That broadens the customer base beyond oil refiners. But Citi's quant team has flagged Ecovyst as one of the most crowded long positions in chemicals , suggesting much of the optimism is already in the stock. The earnings beat is real; whether the stock can hold these gains depends on proving Calabrian's value beyond one good quarter.